A COLLABORATIVE PRACTICE AGREEMENT FOR OPIOID OVERDOSE PREVENTION AND RESPONSE NALOXONE OVERDOSE KIT DISTRIBUTION PROTOCOL

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "A COLLABORATIVE PRACTICE AGREEMENT FOR OPIOID OVERDOSE PREVENTION AND RESPONSE NALOXONE OVERDOSE KIT DISTRIBUTION PROTOCOL"

Transcription

1 A COLLABORATIVE PRACTICE AGREEMENT FOR OPIOID OVERDOSE PREVENTION AND RESPONSE NALOXONE OVERDOSE KIT DISTRIBUTION PROTOCOL Purpose: To reduce morbidity and mortality from opioid overdose. Policy: Under this collaborative practice agreement, in accordance with Utah Code 58-17b-102 and Utah Rules R58-17b-611, eligible pharmacists, may initiate naloxone overdose kit distribution and educate patients based on the criteria below. Education/skills required for eligibility: Eligible pharmacists must be able to perform any of the following related to drug overdoses: Educate individuals on opioid overdose prevention Educate individuals on reducing the risk of prescription opioid abuse Provide information on the safe use of opioids for the management of chronic pain Use screening tools to detect opioid abuse or dependency and provide specialist referrals for management of difficult individuals Means to prevent diversion of prescribed opioid medications Recommend treatment for patients with pain and addiction How to administer naloxone in intranasal and intramuscular dosage forms Naloxone Overdose Kit description: 1) Intra-nasal kit: a. Naloxone 1mg/ml in vial or syringe with luer-lock tip #2 b. Nasal spray luer-lock adapter #2 2) Intramuscular kit: a. Naloxone 0.4mg/ml vial or syringe (or FDA approved naloxone auto-injector device) #2 b. Syringe for IM administration (3 cc x 1 inch needle) #2 3) Evzio (naloxone) intramuscular device. All kits will also contain: a. Instruction card b. Label with expiration date and instructions related to expired or used kit contents c. Optional:

2 i) CPR face shield ii) Vinyl/latex gloves Procedure: 1. [INSERT PHARMACY HERE] pharmacists will identify patients eligible for participation in naloxone overdose kit distribution, meeting any of the criteria of overdose risk: a. Voluntary request from patient, family member or friend b. Recipient of emergency medical care for acute opioid poisoning c. Suspected illicit or nonmedical opioid user d. High dose opioid prescription (>100 morphine equivalence per day) e. Any methadone prescription to opioid naïve patient f. Any opioid prescription and smoking/copd or other respiratory illness or obstruction g. Any opioid prescription for patients with renal dysfunction or hepatic disease h. Any opioid prescription and known or suspected concurrent alcohol use i. Any opioid prescription and concurrent benzodiazepine prescription j. Any opioid prescription and concurrent SSRI or TCA anti-depressant prescription k. Release prisoners from correctional facilities l. Release from opioid detoxification and mandatory abstinence program m. Patients entering methadone maintenance treatment programs (for addition or pain) An additional consideration may be: Patients who may have difficulty accessing emergency medical services 2. Pharmacists will be allowed to initiate naloxone prescriptions if individual meets criteria above: a. Naloxone HCl will be dispensed for intramuscular or intranasal administration (as noted above) b. Naloxone must have a shelf life of at least 12 months at time of dispensing c. Before dispensing naloxone, the pharmacist shall ensure that patients are properly trained in over opioid overdose recognition, response, and naloxone administration 3. Prior to providing services to patients pursuant to this CPA, the pharmacy will obtain informed consent from each patient, which shall include: a. A signed authorization for the release of protected health information by and between the pharmacy and the Collaborating Physician b. A provision allowing the patient to withdraw at any time from the collaborative practice described in this CPA c. An acknowledgment that patient has been offered the education and training d. Pharmacy will retain a copy of the informed consent 4. Pharmacists will provide patient education on the following:

3 a. Purpose for Naloxone, correct way to administer Naloxone, precautions regarding medications that may interact with Naloxone. b. High-risk overdose situations, risk reduction strategies, and appropriate response sets in addition to Naloxone administration, including rescue breathing and call 911. c. Review indications for use and naloxone administration. 5. Pharmacists will document each patient s participation information by the following: a. Record the date the prescription was dispensed, the manufacturer and lot number, and the name and title of the person providing mediation and education. b. Provide written notification via fax to medical provider listed on collaborative agreement of patient participation and/or naloxone dispensing within 7 days. c. Maintain records for a minimum or 5 years i. Informed consent ii. Prescription fill/re-fill records iii. Log of monthly activity to be reviewed by collaborating physician iv. Licensing and liability insurance information of participating pharmacist(s) and prescriber (s) will be maintained 6. Contact the medical provider listed on collaborative agreement in the event that the pharmacist requires medical consultation for a particular patient. 7. The collaborating medical provider may override a collaborative practice decision made by the pharmacist, if appropriate and/or in the best interest of the patient 8. Both parties shall maintain a copy of licensing and liability insurance information in their respective records for both the pharmacist and physician named below. This policy and procedure shall remain in effect for 2 years after the effective date unless rescinded earlier. Physician or Medical Provider Date Utah License number Pharmacist Date

4 Utah License number Date of implementation: Proof of liability insurance will be included for above signatories in the appendix to this document.

5 Title. This chapter is known as the Emergency Administration of Opiate Antagonist Act Definitions. As used in this chapter: (1) Health care facility means a hospital, a hospice inpatient residence, a nursing facility, a dialysis treatment facility, an assisted living residence, an entity that provides home- and community-based services, a hospice or home health care agency, or another facility that provides or contracts to provide health care services, which facility is licensed under Chapter 21, Health Care Facility Licensing and Inspection Act. (2) Health care provider means: (a) a physician as defined in Section ; (b) an advanced practice registered nurse as defined in Subsection 58-31b-102(13); or (c) a physician assistant as defined in Section 58-70a-102. (3) Opiate is as defined in Section (4) Opiate antagonist means naloxone hydrochloride or any similarly acting drug that is not a controlled substance and that is approved by the federal Food and Drug Administration for the treatment of a drug overdose. (5) Opiate-related drug overdose event means an acute condition, including a decreased level of consciousness or respiratory depression resulting from the consumption or use of a controlled substance, or another substance with which a controlled substance was combined, and that a person would reasonably believe to require medical assistance Voluntary participation. This chapter does not create a duty or standard of care for a person to prescribe or administer an opiate antagonist Authority to obtain and use an emergency opiate antagonist -- Immunity from liability. (1) (a) Except as provided in Subsection (1)(b), a person other than a health care facility or health care provider who acts in good faith to administer an opiate antagonist to another person whom the person believes to be suffering an opiate-related drug overdose event is not liable for any civil damages or acts or omissions made as a result of administering the opiate antagonist. (b) A health care provider: (i) does not have immunity from liability under Subsection (1)(a) when the health care provider is acting within the scope of the health care provider s responsibilities or duty of care; and (ii) does have immunity from liability under Subsection (1)(a) if the health care provider is under no legal duty to respond and otherwise complies with Subsection (1)(a).

6 (2) Notwithstanding Sections , 58-17b-501, and 58-17b-502, a health care provider who is licensed to prescribe or dispense an opiate antagonist may, without a prescriber-patient relationship, prescribe or dispense an opiate antagonist without liability for any civil damages or acts or omissions made as a result of prescribing or dispensing an opiate antagonist in good faith, to: (a) an individual who is at increased risk of experiencing or who is likely to experience an opiate-related drug overdose event; or (b) a family member of, friend of, or other person who may be in a position to assist an individual who may be at increased risk of experiencing or who is likely to experience an opiate-related drug overdose event. (3) A person who prescribes or dispenses an opiate antagonist shall provide education to the individual described in Subsection (2)(a) or (b) that includes instructions to take the person who received the opiate antagonist to an emergency care facility for a medical evaluation. Enacted by Chapter 130, 2014 General Session

7

8 Detach for patient Naloxone for Overdose Prevention patient name date of birth patient address patient city, state, ZIP code prescriber name prescriber address prescriber city, state, ZIP code prescriber phone number Naloxone HCl 1 mg/ml 2 x 2 ml as pre-filleld Luer-Lock needless syringe (NDC ) Refills: 2 x Intranasal Mucosal Atomizing Device (MAD 300) Refills: For suspected opioid overdose, spray 1mL in each nostril. Repeat after 3 minutes if no or minimal response. Pharmacist: Call to order MAD 300. prescriber signature date How to Avoid Overdose Only take medicine prescribed to you Don t take more than instructed Call a doctor if your pain gets worse Never mix pain meds with alcohol Avoid sleeping pills when taking pain meds Dispose of unused medications Store your medicine in a secure place Learn how to use naloxone Teach your family + friends how to respond to an overdose Are they breathing? Signs of an overdose: Slow or shallow breathing Gasping for air when sleeping or weird snoring Pale or bluish skin Slow heartbeat, low blood pressure Won t wake up or respond (rub knuckles on sternum) Airway Make sure nothing is inside the person's mouth. Prepare Naloxone Are they any better? Can you get naloxone and prepare it quickly enough that they won t go for too long without your breathing assistance? Call 911 for help All you have to say: Someone is unresponsive and not breathing. Give clear address and location. Rescue breathing Oxygen saves lives. Breathe for them. One hand on chin, tilt head back, pinch nose closed. Make a seal over mouth & breathe in 1 breath every 5 seconds Chest should rise, not stomach PrescribeToPrevent.org 1 Pull or pry off yellow caps 2 Pry off red cap PLASTIC TUBE NALOXONE 5 Insert white cone into nostril; give a short, vigorous push on end of capsule to spray naloxone into nose: one half of the capsule into each nostril. 3 Grip clear plastic wings. 4 Gently screw capsule of naloxone into barrel of tube. If no reaction in 3 6 minutes, give the second dose. Push to spray. Source: HarmReduction.org Evaluate + support Continue rescue breathing Give another 2 sprays of naloxone in 3 minutes if no or minimal breathing or responsiveness Naloxone wears off in minutes Comfort them; withdrawal can be unpleasant Get them medical care and help them not use more opiate right away Encourage survivors to seek treatment if they feel they have a problem v

9 How to Use EVZIO Visual and voice instructions help guide the way EVZIO is designed to be easy to use for patients, their family members, and other caregivers who do not have medical training. 1 It contains the Intelliject Prompt System (IPS ) with visual and voice instructions that help guide the user through the injection process. Administration steps 1- Pull EVZIO from the outer case. Do not go to Step 2 (do not remove the red safety guard) until you are ready to use EVZIO. If you are not ready to use EVZIO, put it back in the outer case for later use. 2- Pull off the red safety guard. To reduce the chance of an accidental injection, do not touch the black base of the auto-injector, which is where the needle comes out. If an accidental injection happens, get medical help right away. Note: The red safety guard is made to fit tightly. Pull firmly to remove. Do not replace the red safety guard after it is removed. 3- Place the black end against the middle of the patient's outer thigh, through clothing (pants, jeans, etc) if necessary, then press firmly and hold in place for 5 seconds. If you give EVZIO to an infant less than 1 year old, pinch the middle of the outer thigh before you give EVZIO and continue to pinch while you give EVZIO. Note: EVZIO makes a distinct sound (click and hiss) when it is pressed against the thigh. This is normal and means that EVZIO is working correctly. Keep EVZIO firmly pressed on the thigh for 5 seconds after you hear the click and hiss sound. The needle will inject and then retract back up into the EVZIO auto-injector and is not visible after use. 4- After using EVZIO, the user should immediately seek emergency medical help. If symptoms return after an injection with EVZIO, an additional injection using another EVZIO may be needed. Give additional injections using a new EVZIO auto-injector every 2 to 3 minutes and continue to closely watch the person until emergency help is received. EVZIO cannot be reused. After use, place the auto-injector back into its outer case. Do not replace the red safety guard. Do not throw away the EVZIO in household trash. Do not recycle EVZIO. Used EVZIO should be taken to a healthcare setting for proper disposal in a sharps container. There may be local or state laws about how to throw away used autoinjectors.*

OPIOID OVERDOSE RESPONSE AND NALOXONE ADMINISTRATION

OPIOID OVERDOSE RESPONSE AND NALOXONE ADMINISTRATION 1.0 Purpose OPIOID OVERDOSE RESPONSE AND NALOXONE ADMINISTRATION This is a DESC internal operational policy and procedure document [effective date: 06/26/2015] Greg Jensen, Director of Administrative Services

More information

OPIOID OVERDOSE PREVENTION ORIENTATION WHAT ARE OPIOIDS AND HOW LONG DO THEY WORK? Duration of Action of Opioids

OPIOID OVERDOSE PREVENTION ORIENTATION WHAT ARE OPIOIDS AND HOW LONG DO THEY WORK? Duration of Action of Opioids OPIOID OVERDOSE PREVENTION ORIENTATION There has been an alarming increase in the incidence of deaths caused by opioid overdose (prescription and non- prescription) in the United States. Enhanced educational

More information

Naloxone treatment of opioid overdose

Naloxone treatment of opioid overdose Naloxone treatment of opioid overdose Opioids Chemicals that act in the brain to relieve pain, often use to suppress cough, treat addiction, and provide comfort After prolonged use of opioids, increasing

More information

Objectives. Background

Objectives. Background Development and Implementation of a Pharmacist-Managed Intranasal Naloxone Distribution Program in a Veterans Affairs Healthcare Facility and Associated Community Clinics Innovative Practices Award Finalist

More information

Opioid Overdose Prevention for Law Enforcement and First Responders. Sponsored by the NC Office of EMS

Opioid Overdose Prevention for Law Enforcement and First Responders. Sponsored by the NC Office of EMS Opioid Overdose Prevention for Law Enforcement and First Responders Sponsored by the NC Office of EMS Overview The goal of this presentation is to help inform the public safety community of North Carolina

More information

Medications to address the opioid crisis - methadone, buprenorphine, naltrexone, and naloxone

Medications to address the opioid crisis - methadone, buprenorphine, naltrexone, and naloxone Medications to address the opioid crisis - methadone, buprenorphine, naltrexone, and naloxone Alexander Y. Walley, MD, MSc Director, Addiction Medicine Fellowship and Addiction Medicine Consult Service

More information

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. DISPENSING OR SELLING NALOXONE Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. UPDATED ON: August 10, 2016 Purpose The intent of this document is to provide

More information

This presentation is going to discuss the BLS use of Intranasal naloxone. Naloxone is the generic name while Narcan is the trade name.

This presentation is going to discuss the BLS use of Intranasal naloxone. Naloxone is the generic name while Narcan is the trade name. Welcome! 1 This presentation is going to discuss the BLS use of Intranasal naloxone. Naloxone is the generic name while Narcan is the trade name. 2 Definitive treatment for an opioid or opiate overdose

More information

Naloxone Rescue for Opioid Reversal

Naloxone Rescue for Opioid Reversal Naloxone Rescue for Opioid Reversal Shannon Panther, PharmD, BCACP Washington State University October 8, 2015 Disclosures No relationships to disclose Intranasal use of naloxone is off label Objectives

More information

Opioid Overdose Prevention Guidelines for Training Responders

Opioid Overdose Prevention Guidelines for Training Responders Opioid Overdose Prevention Guidelines for Training Responders Oct 31, 2006 OD Oct 31, 2006 Opioid Overdose Prevention Guidelines for Training Responders BACKGROUND Introduction Opioid overdose is a serious

More information

CHAPTER 10. 1. Section 3 of P.L.2013, c.46 (C.24:6J-3) is amended to read as follows:

CHAPTER 10. 1. Section 3 of P.L.2013, c.46 (C.24:6J-3) is amended to read as follows: CHAPTER 10 AN ACT concerning overdose prevention and sterile syringe access programs, and amending P.L.2006, c.99 and P.L.2013, c.46. BE IT ENACTED by the Senate and General Assembly of the State of New

More information

JAN 2 7 2016. poisonings, commonly referred to as drug overdoses, are one of. the leading causes of injury-related mortality in Hawaii.

JAN 2 7 2016. poisonings, commonly referred to as drug overdoses, are one of. the leading causes of injury-related mortality in Hawaii. THE SENATE TWENTY-EIGHTH LEGISLATURE, 0 STATE OF HAWAII JAN 0 A BILL FOR AN ACT S.B. NO. % RELATING TO DRUG OVERDOSE PREVENTION BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII: 0 SECTION. The legislature

More information

Disclosure. State of Connecticut Naloxone Training Program. Introduction. Objectives. Epidemiology. Background 3/4/2016

Disclosure. State of Connecticut Naloxone Training Program. Introduction. Objectives. Epidemiology. Background 3/4/2016 State of Connecticut Naloxone Training Program Developed by: Department of Consumer Protection Drug Control Division Connecticut Pharmacists Association Department of Mental Health and Addiction Services

More information

DRAFT OVERDOSE ASSESSMENT, RESPONSE AND TREATMENT POLICY FOR SELECTED ADULT FACILITES

DRAFT OVERDOSE ASSESSMENT, RESPONSE AND TREATMENT POLICY FOR SELECTED ADULT FACILITES 1 DRAFT OVERDOSE ASSESSMENT, RESPONSE AND TREATMENT POLICY FOR SELECTED ADULT FACILITES PURPOSE To provide guidelines for staff response when a client is found unconscious or not breathing. APPLICABILITY

More information

INSTRUCTIONS FOR USE. Read this information before you start. Important things to know about your SmartJect autoinjector. Important things to remember

INSTRUCTIONS FOR USE. Read this information before you start. Important things to know about your SmartJect autoinjector. Important things to remember INSTRUCTIONS FOR USE SIMPONI (SIM-po-nee) (golimumab) SmartJect autoinjector If your doctor decides that you or a caregiver may be able to give your injections of SIMPONI at home, you should receive training

More information

OPTIONAL LESSON Anaphylaxis and Epinephrine Auto-Injector

OPTIONAL LESSON Anaphylaxis and Epinephrine Auto-Injector OPTIONAL LESSON Anaphylaxis and Epinephrine Auto-Injector Lesson Length: 54 minutes GUIDANCE FOR THE INSTRUCTOR To complete this lesson and meet the lesson objectives, you must: Discuss all points in the

More information

Overdose Response Training

Overdose Response Training Overdose Response Training In collaboration with the Massachusetts Department of Public Health, Bureau of Substance Abuse Services and Office of HIV/AIDS The Overdose Problem National & regional drug threat

More information

EXPLORING NALOXONE UPTAKE AND USE PUBLIC MEETING July 01 02, 2015 Fred Wells Brason II fbrason@projectlazarus.org

EXPLORING NALOXONE UPTAKE AND USE PUBLIC MEETING July 01 02, 2015 Fred Wells Brason II fbrason@projectlazarus.org EXPLORING NALOXONE UPTAKE AND USE PUBLIC MEETING July 01 02, 2015 Fred Wells Brason II fbrason@projectlazarus.org Disclosures Project Lazarus Zogenix Charitable Contribution 2015 Kaléo Charitable Contribution

More information

NOTE: The governor signed this measure on 5/10/2013.

NOTE: The governor signed this measure on 5/10/2013. NOTE: The governor signed this measure on 5/10/2013. SENATE BILL 13-014 BY SENATOR(S) Aguilar, Guzman, Kefalas, Newell, Steadman, Tochtrop, Todd, Ulibarri; also REPRESENTATIVE(S) Pettersen, Fields, Ginal,

More information

Instructions for Use Aranesp (Air-uh-nesp) (darbepoetin alfa) Injection Single-Dose Prefilled Syringe (SingleJect )

Instructions for Use Aranesp (Air-uh-nesp) (darbepoetin alfa) Injection Single-Dose Prefilled Syringe (SingleJect ) Instructions for Use Aranesp (Air-uh-nesp) (darbepoetin alfa) Injection Single-Dose Prefilled Syringe (SingleJect ) Guide to parts Before use After use Plunger rod Used plunger rod Finger grip Label and

More information

PURPOSES OF TREATING INDIVIDUALS WHO MAY EXPERIENCE AN OPIATE-RELATED DRUG OVERDOSE EVENT.

PURPOSES OF TREATING INDIVIDUALS WHO MAY EXPERIENCE AN OPIATE-RELATED DRUG OVERDOSE EVENT. NOTE: This bill has been prepared for the signatures of the appropriate legislative officers and the Governor. To determine whether the Governor has signed the bill or taken other action on it, please

More information

Instructions For Use PRALUENT (PRAHL-u-ent) (alirocumab) Injection, for Subcutaneous Injection Single-Dose Pre-Filled Syringe (75 mg/ml)

Instructions For Use PRALUENT (PRAHL-u-ent) (alirocumab) Injection, for Subcutaneous Injection Single-Dose Pre-Filled Syringe (75 mg/ml) Instructions For Use PRALUENT (PRAHL-u-ent) (alirocumab) Injection, for Subcutaneous Injection Single-Dose Pre-Filled Syringe (75 mg/ml) Important Information The device is a single-dose pre-filled syringe.

More information

Naloxone for Opioid Overdose: FAQs

Naloxone for Opioid Overdose: FAQs PL Detail-Document #310702 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER July 2015 Naloxone for Opioid

More information

Opioid overdose can occur when a patient misunderstands the directions

Opioid overdose can occur when a patient misunderstands the directions Facts About Opioid Overdose How Does an Overdose Occur? Opioid overdose can occur when a patient misunderstands the directions for use, accidentally takes an extra dose, or deliberately misuses a prescription

More information

Includes. How to give naloxone. Overdose. Everything you need to know. Includes free DVD!

Includes. How to give naloxone. Overdose. Everything you need to know. Includes free DVD! Includes How to give naloxone Overdose Everything you need to know Includes free DVD! Please read this booklet. We guarantee you ll learn something new. When you ve read it, you ll know about overdose

More information

SENATE BILL 871. By Dickerson BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE:

SENATE BILL 871. By Dickerson BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE: SENATE BILL 871 By Dickerson AN ACT to amend Tennessee Code Annotated, Title 33; Title 53; Title 56 and Title 63, relative to substance abuse. BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE:

More information

Transcript: DMHAS Overdose Responder Training

Transcript: DMHAS Overdose Responder Training Transcript: DMHAS Overdose Responder Training #1 TITLE SLIDE. #2 INTRODUCTION AND PURPOSE Welcome to Overdose Responder training presented by the NJ Department of Human Services / Division of Mental Health

More information

GD-112-PHS-EMS: Curriculum for Law Enforcement/EMT Administration of Naloxone in the Pre-Hospital Setting

GD-112-PHS-EMS: Curriculum for Law Enforcement/EMT Administration of Naloxone in the Pre-Hospital Setting STATE OF ARIZONA EMERGENCY MEDICAL SERVICES AND TRAUMA SYSTEM Curriculum for Law Enforcement/EMT Administration of Naloxone in the Course Description This course is designed to provide instruction in a

More information

Version Number: 5. Patient Group Direction originally drawn up by: Reviewed by: Patient Group direction authorised by: Medical Lead

Version Number: 5. Patient Group Direction originally drawn up by: Reviewed by: Patient Group direction authorised by: Medical Lead PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY AND/OR ADMINISTRATION OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES WORKING IN COMMUNITY AND INPATIENT SUBSTANCE MISUSE TEAMS Version Number: 5 Patient

More information

New Law Advisory. Advisory No. 2013-13 Issued: May 17, 2013. P.L. 2013, c.46 - The "Opioid Antidote and Overdose Protection Act"

New Law Advisory. Advisory No. 2013-13 Issued: May 17, 2013. P.L. 2013, c.46 - The Opioid Antidote and Overdose Protection Act Administrative Office of the Courts Office of Professional and Governmental Services Glenn A. Grant, J.A.D. Acting Administrative Director of the Courts New Law Advisory Deirdre Naughton Director, Professional

More information

OPIOID OVERDOSE AVERTED: NALOXONE-FRIENDLY ZONES SAVE LIVES. Carl Scroggins, CADC, QHEIC, EMT

OPIOID OVERDOSE AVERTED: NALOXONE-FRIENDLY ZONES SAVE LIVES. Carl Scroggins, CADC, QHEIC, EMT OPIOID OVERDOSE AVERTED: NALOXONE-FRIENDLY ZONES SAVE LIVES Carl Scroggins, CADC, QHEIC, EMT For the audio portion of this webinar, you have two options. 1. Listen through your computer speakers. Just

More information

16.19.10.11 PUBLIC HEALTH CLINICS: A. CLINIC LICENSURE: (1) All clinics where dangerous drugs are administered, distributed or dispensed shall obtain

16.19.10.11 PUBLIC HEALTH CLINICS: A. CLINIC LICENSURE: (1) All clinics where dangerous drugs are administered, distributed or dispensed shall obtain 16.19.10.11 PUBLIC HEALTH CLINICS: A. CLINIC LICENSURE: (1) All clinics where dangerous drugs are administered, distributed or dispensed shall obtain a limited drug permit as described in Section 61-11-14

More information

NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS

NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS This project was supported by Grant No. G1299ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this

More information

D R A F T SUMMARY. prescription monitoring information submitted under ORS 431A.860 to

D R A F T SUMMARY. prescription monitoring information submitted under ORS 431A.860 to LC 0 Regular Session // (SCT/ps) D R A F T SUMMARY Requires Oregon Health Authority to disclose prescription monitoring information to practitioner or pharmacist or member of practitioner s or pharmacist

More information

Section 400: Code # 453.4R

Section 400: Code # 453.4R Section 400: Code # 453.4R Administering Medication Conditions for Administering Prescription Drugs Except as otherwise specifically provided by law, a school bus driver, employee, or volunteer that has

More information

Instructions for Use

Instructions for Use 1 Instructions for Use HUMULIN R U-500 KwikPen insulin human injection U-500 (500 units/ml, 3 ml pen) Important: Know your dose of HUMULIN R U-500 insulin. The Pen delivers your dose in insulin units.

More information

Education. The Council of Southeast Pennsylvania, Inc. Overdose Prevention and. Education Advisory Board

Education. The Council of Southeast Pennsylvania, Inc. Overdose Prevention and. Education Advisory Board Overdose Prevention and Education The Council of Southeast Pennsylvania, Inc. Overdose Prevention and Education Advisory Board Outline What is an Overdose? What drugs are we talking about? Risk Factors

More information

How To Prepare and Give a Prefilled Syringe Injection

How To Prepare and Give a Prefilled Syringe Injection Diablo Valley Onc&Hem Med Grp, Inc Phone Number: (925)6775041 How To Prepare and Give a Prefilled Syringe Injection Patient Education Quick Reference Guide The following are instructions for use of prefilled

More information

Verbalize knowledge of laws and policies for administration of prescribed and over the counter medication to students.

Verbalize knowledge of laws and policies for administration of prescribed and over the counter medication to students. Medication Administration for Non-Licensed School Staff Canton City Schools School Health Issues: A federal mandate created in the 1970s obligated schools to provide children with medical services, including

More information

First Regular Session Sixty-ninth General Assembly STATE OF COLORADO INTRODUCED HOUSE SPONSORSHIP

First Regular Session Sixty-ninth General Assembly STATE OF COLORADO INTRODUCED HOUSE SPONSORSHIP First Regular Session Sixty-ninth General Assembly STATE OF COLORADO INTRODUCED LLS NO. 1-0.01 Richard Sweetman x SENATE BILL 1-01 SENATE SPONSORSHIP Aguilar, (None), HOUSE SPONSORSHIP Senate Committees

More information

Heart problems - What are the possible side effects of AVONEX? What is AVONEX? Who should not take AVONEX?

Heart problems - What are the possible side effects of AVONEX? What is AVONEX? Who should not take AVONEX? MEDICATION GUIDE AVONEX Interferon beta-1a (Including appendix with instructions for using AVONEX Vials) Please read this guide carefully before you start to use AVONEX (a-vuh-necks) and each time your

More information

Epinephrine Administration Training for Unlicensed School Personnel

Epinephrine Administration Training for Unlicensed School Personnel Epinephrine Administration Training for Unlicensed School Personnel Management of Life-Threatening Allergies in the School Setting Dover and Sherborn Schools EpiPen Administration This program is designed

More information

BROCKTON AREA MULTI-SERVICES, INC. MEDICAL PROCEDURE GUIDE. Date(s) Reviewed/Revised:

BROCKTON AREA MULTI-SERVICES, INC. MEDICAL PROCEDURE GUIDE. Date(s) Reviewed/Revised: Page 1 of 5 PROCEDURE FOR: MAP-certified staff and RN/LPN MAP-certified staff are to be trained in the use of epinephrine administration via pre-filled autoinjector devices(s) annually. Certified staff

More information

Information for Pharmacists

Information for Pharmacists Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl

More information

NIH Clinical Center Patient Education Materials Giving a subcutaneous injection

NIH Clinical Center Patient Education Materials Giving a subcutaneous injection NIH Clinical Center Patient Education Materials What is a subcutaenous injection? A subcutaneous injection is given in the fatty layer of tissue just under the skin. A subcutaneous injection into the fatty

More information

Liberty Union High School District Administrative Regulation

Liberty Union High School District Administrative Regulation Page 1 of 7 Definitions Authorized health care provider means an individual who is licensed by the State of California to prescribe or order medication, including, but not limited to, a physician or physician

More information

NEW YORK STATE DEPARTMENT OF HEALTH BUREAU OF EMERGENCY MEDICAL SERVICES

NEW YORK STATE DEPARTMENT OF HEALTH BUREAU OF EMERGENCY MEDICAL SERVICES NEW YORK STATE DEPARTMENT OF HEALTH BUREAU OF EMERGENCY MEDICAL SERVICES TRAINING PROGRAM OUTLINE FOR UNLICENSED OR UNCERTIFIED PERSONNEL TO ADMINISTER EPINEPHRINE BY AUTO-INJECTOR IN LIFE-THREATENING

More information

Instructions for Use PROCRIT (PRO KRIT) (epoetin alfa)

Instructions for Use PROCRIT (PRO KRIT) (epoetin alfa) Instructions for Use PROCRIT (PROKRIT) (epoetin alfa) Use these Instructions for Use if you or your caregiver has been trained to give PROCRIT injections at home. Do not give yourself the injection unless

More information

Food Allergy Action Plan

Food Allergy Action Plan Food Allergy Action Plan Name: D.O.B.: / / Allergy to: Weight: lbs. Asthma: Yes (higher risk for a severe reaction) No Place Student s Picture Here Extremely reactive to the following foods: THEREFORE:

More information

Instructions for Use HUMALOG KwikPen insulin lispro injection (rdna origin)

Instructions for Use HUMALOG KwikPen insulin lispro injection (rdna origin) 1 Instructions for Use HUMALOG KwikPen insulin lispro injection (rdna origin) Read the Instructions for Use before you start taking HUMALOG and each time you get a refill. There may be new information.

More information

Medication Administration for Non-Licensed School Staff

Medication Administration for Non-Licensed School Staff Medication Administration for Non-Licensed School Staff School Health Issues A federal mandate created in the 1970s obligated schools to provide children with medical services, including medication administration.

More information

Intramuscular (IM) Self-Injection

Intramuscular (IM) Self-Injection Intramuscular (IM) Self-Injection What is an Intramuscular Injection? An intramuscular injection, as illustrated in the figure below, delivers medication deep into the muscle tissue. This allows the medication

More information

Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1)

Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1) Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1) This Influenza Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses (

More information

1. Dosing Schedule: your customized schedule of your weekly injections as provided by the center.

1. Dosing Schedule: your customized schedule of your weekly injections as provided by the center. Home Immunotherapy Raza Pasha, MD Congratulations. You are now on the path to better control of your allergies. The following is your instruction guide to allow you to become more familiar with proper

More information

Giving Yourself Dalteparin (Fragmin) or Heparin

Giving Yourself Dalteparin (Fragmin) or Heparin Contents www.bcwomens.ca What is Dalteparin (Fragmin)...1 Where do I get this medication from?...1 How often do I give myself this medication?...1 Side effects...1 Steps to Giving Yourself Dalteparin (Fragmin)..1

More information

Irish Poet, Rev John Donne

Irish Poet, Rev John Donne No man is an island entire of itself; any man's death diminishes me, because I am involved in mankind therefore never send to know for whom the bell tolls; it tolls for thee. Irish Poet, Rev John Donne

More information

- NALOXONE/NARCAN. This training is designed to teach you about one action you can take in case of an overdose of opiates.

- NALOXONE/NARCAN. This training is designed to teach you about one action you can take in case of an overdose of opiates. OVERDOSE MANAGEMENT PROTOCOL - NALOXONE/NARCAN TRAINING This training is designed to teach you about one action you can take in case of an overdose of opiates. This training program will not make you a

More information

P U B L I C H E A L T H A D V I S O R Y

P U B L I C H E A L T H A D V I S O R Y The Commonwealth of Massachusetts Executive Office of Health and Human Services Department of Public Health 250 Washington Street, Boston, MA 02108-4619Tel: 617-624-6000 Fax: 617-624-5206 www.mass.gov/dph

More information

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. SOMAVERT pegvisomant for injection PATIENT INFORMATION SOMAVERT (SOM-ah-vert) (pegvisomant for injection) Read the patient information that comes with SOMAVERT before you start using it and each time you

More information

Nebulized Colistimethate (Coly-Mycin ) or Colistin

Nebulized Colistimethate (Coly-Mycin ) or Colistin Nebulized Colistimethate (Coly-Mycin ) or Colistin Indication for use of this Medicine Colistimethate is used to treat lung infections caused by Pseudomonas, a type of bacteria. Dose - Either 75 mg or

More information

Learning to Self Inject Methotrexate at Home Developed by Andy Thompson MD FRCPC and Marie J Craig-Chambers B.Sc.Phm

Learning to Self Inject Methotrexate at Home Developed by Andy Thompson MD FRCPC and Marie J Craig-Chambers B.Sc.Phm Learning to Self Inject Methotrexate at Home Developed by Andy Thompson MD FRCPC and Marie J Craig-Chambers B.Sc.Phm Why might my Doctor ask me to inject Methotrexate? Methotrexate comes in two forms:

More information

Share the important information in this Medication Guide with members of your household.

Share the important information in this Medication Guide with members of your household. MEDICATION GUIDE BUPRENORPHINE (BUE-pre-NOR-feen) Sublingual Tablets, CIII IMPORTANT: Keep buprenorphine sublingual tablets in a secure place away from children. Accidental use by a child is a medical

More information

Package leaflet: Information for the patient. Naloxone Hydrochloride 20 micrograms / ml Solution for Injection Naloxone hydrochloride

Package leaflet: Information for the patient. Naloxone Hydrochloride 20 micrograms / ml Solution for Injection Naloxone hydrochloride A leaflet will be included in each pack. The leaflet will consist of a Technical Information Leaflet and a Patient Information Leaflet. The two leaflets will be easily separatable. The text of the Technical

More information

INSTRUCTIONS FOR USE HUMIRA 40 MG/0.8 ML SINGLE-USE PEN

INSTRUCTIONS FOR USE HUMIRA 40 MG/0.8 ML SINGLE-USE PEN INSTRUCTIONS FOR USE HUMIRA (Hu-MARE-ah) (adalimumab) 40 MG/0.8 ML SINGLE-USE PEN Do not try to inject HUMIRA yourself until you have been shown the right way to give the injections and have read and understand

More information

Emergency Treatment of an Anaphylactic Reaction in the Community Protocol

Emergency Treatment of an Anaphylactic Reaction in the Community Protocol Emergency Treatment of an Anaphylactic Reaction in the Community Protocol Reference Number: NHSCT/09/216 Responsible Directorate: Children s Services Replaces (if appropriate): Northern Trust Departmental

More information

What you should know about treating your pain with opioids. Important information on the safe use of opioid pain medicine.

What you should know about treating your pain with opioids. Important information on the safe use of opioid pain medicine. What you should know about treating your pain with opioids Important information on the safe use of opioid pain medicine. If your healthcare provider has determined that opioid therapy is right for you,

More information

Collaborative Drug Therapy Agreement for Naloxone Medication in Opioid Overdose Reversal

Collaborative Drug Therapy Agreement for Naloxone Medication in Opioid Overdose Reversal Collaborative Drug Therapy Agreement for Naloxone Medication in Opioid Overdose Reversal I,, MD, a licensed health care provider authorized to prescribe medication in the State of Washington, delegate

More information

Overdose Education in Medical Settings

Overdose Education in Medical Settings Overdose Education in Medical Settings Where is the patient at as far as overdose? Ask your patients whether they have overdosed, witnessed an overdose or received training to prevent, recognize, or respond

More information

Guidelines for the Use of Naloxone in Palliative Care in Adult Patients

Guidelines for the Use of Naloxone in Palliative Care in Adult Patients Guidelines for the Use of Naloxone in Palliative Care in Adult Patients Date Approved by Network Governance May 2012 Date for Review May 2015 Changes between Version 1 and 2 1. Guideline background 2.

More information

California SB-486 Plan Revision Date: July 1, 2014. Plan for Supporting Safe Collection and Proper Disposal of Home Generated Sharps

California SB-486 Plan Revision Date: July 1, 2014. Plan for Supporting Safe Collection and Proper Disposal of Home Generated Sharps Plan for Supporting Safe Collection and Proper Disposal of Home Generated Sharps Background: The State of California recently enacted two laws to address home generated sharps disposal. The first law (SB

More information

Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care

Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care Hull & East Riding Prescribing Committee Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care 1. BACKGROUND Patients who are physically dependent

More information

Massachusetts Department of Public Health Opioid Overdose Education and Naloxone Distribution. MDPH Naloxone pilot project Core Competencies

Massachusetts Department of Public Health Opioid Overdose Education and Naloxone Distribution. MDPH Naloxone pilot project Core Competencies Massachusetts Department of Public Health Opioid Overdose Education and Naloxone Distribution MDPH Naloxone pilot project Core Competencies Acknowledgements: Thank you to the Boston Public Health Commission

More information

Instructions for use: Repatha (ri-path-a) (evolocumab) Single-Use Prefilled Syringe. Guide to parts

Instructions for use: Repatha (ri-path-a) (evolocumab) Single-Use Prefilled Syringe. Guide to parts Instructions for use: Repatha (ri-path-a) (evolocumab) Single-Use Prefilled Syringe Before use Plunger rod Guide to parts Used plunger After use Used syringe barrel Medicine Syringe barrel Used Needle

More information

MASSACHUSETTS. Downloaded January 2011

MASSACHUSETTS. Downloaded January 2011 MASSACHUSETTS Downloaded January 2011 150.007 NURSING SERVICES (G) Nursing and Supportive Routines and Practices. (2) No medication, treatment or therapeutic diet shall be administered to a patient or

More information

New Jersey EMS Response to an Opiate Overdose Naloxone (Narcan ) Program **Updated March 26, 2015**

New Jersey EMS Response to an Opiate Overdose Naloxone (Narcan ) Program **Updated March 26, 2015** New Jersey EMS Response to an Opiate Overdose Naloxone (Narcan ) Program **Updated March 26, 2015** Disclaimer This presentation was created to assist in the education of EMTs in Naloxone administration.

More information

Care Management Council submission date: August 2013. Contact Information

Care Management Council submission date: August 2013. Contact Information Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing

More information

INSULIN INJECTION KNOW-HOW

INSULIN INJECTION KNOW-HOW 0-0- INSULIN INJECTION KNOW-HOW Learning how to Congratulations for making the move to insulin therapy. It won t be long before you start enjoying better blood sugar control, more energy, and a host of

More information

MEDICATION MANUAL Policy & Procedure

MEDICATION MANUAL Policy & Procedure MEDICATION MANUAL Policy & Procedure TITLE: Section: Initial Management of Anaphylaxis Following Immunization Medication Specific NUMBER: MM 20-005 Date Issued: October 2009 Source: Distribution: Capital

More information

Copyright 2014 St. Jude Children's Research Hospital Page 1 of 5 Revised 8/14

Copyright 2014 St. Jude Children's Research Hospital  Page 1 of 5 Revised 8/14 Enoxaparin (also known as Lovenox or low molecular weight heparin) is a blood thinner (anticoagulant). It is used to treat patients who have a blood clot. It can also be used to prevent blood clots in

More information

It is important that you tell your family and the people closest to you of this increased sensitivity to opioids and the risk of overdose.

It is important that you tell your family and the people closest to you of this increased sensitivity to opioids and the risk of overdose. MEDICATION GUIDE VIVITROL (viv-i-trol) (naltrexone for extended-release injectable suspension) Read this Medication Guide before you start receiving VIVITROL injections and each time you receive an injection.

More information

FRAGMIN Please bring this booklet the day of your surgery.

FRAGMIN Please bring this booklet the day of your surgery. FRAGMIN Please bring this booklet the day of your surgery. QHC#72 Fragmin (dalteparin sodium injection); an anticoagulant (blood thinner) is used to help prevent blood clots after surgery. While on Fragmin,

More information

Injection Guide for MENOPUR (menotropins for injection)

Injection Guide for MENOPUR (menotropins for injection) Injection Guide for MENOPUR (menotropins for injection) Your doctor has prescribed MENOPUR for subcutaneous injection. This instruction guide will help you prepare and inject yourself with MENOPUR at home.

More information

International Overdose Awareness Day August 31, 2015

International Overdose Awareness Day August 31, 2015 International Overdose Awareness Day August 31, 2015 Statewide TASC Substance Abuse Evaluators Educational Presentation Jayne Cavanaugh, New Jersey Drug Courts Prevalence of Overdose Deaths per Centers

More information

Naloxone Distribution for Opioid Overdose Prevention

Naloxone Distribution for Opioid Overdose Prevention Naloxone Distribution for Opioid Overdose Prevention Caleb Banta-Green PhD, MPH, MSW Alcohol and Drug Abuse Institute, University of Washington Alan Melnick, MD, MPH Clark County Public Health Chris Humberson,

More information

Vaccine Protocol Agreement. Name of Pharmacy: Address: City, State, Zip:

Vaccine Protocol Agreement. Name of Pharmacy: Address: City, State, Zip: Vaccine Protocol Agreement Name of Pharmacy: Address: City, State, Zip: This Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses ( Nurses

More information

Instructions for Use. TRULICITY (Trū-li-si-tee) (dulaglutide) injection, for subcutaneous use. 0.75 mg/0.5 ml Single-Dose Pen.

Instructions for Use. TRULICITY (Trū-li-si-tee) (dulaglutide) injection, for subcutaneous use. 0.75 mg/0.5 ml Single-Dose Pen. Instructions for Use 1 TRULICITY (Trū-li-si-tee) (dulaglutide) injection, for subcutaneous use 0.75 mg/0.5 ml Single-Dose Pen once weekly BREAK SEAL BREAK SEAL Unfold and lay flat Read both sides for full

More information

OVERDOSE EDUCATION & NALOXONE DISTRIBUTION (OEND) IN MICHIGAN P A M E L A L Y N C H, L L M S W, C A A D C W H O S O E V E R C O L L A B O R A T I V E

OVERDOSE EDUCATION & NALOXONE DISTRIBUTION (OEND) IN MICHIGAN P A M E L A L Y N C H, L L M S W, C A A D C W H O S O E V E R C O L L A B O R A T I V E OVERDOSE EDUCATION & NALOXONE DISTRIBUTION (OEND) IN MICHIGAN P A M E L A L Y N C H, L L M S W, C A A D C W H O S O E V E R C O L L A B O R A T I V E Sales of opioids: Michigan is above the median in

More information

Opioid Overdose and Intranasal Naloxone Training for Law Enforcement

Opioid Overdose and Intranasal Naloxone Training for Law Enforcement Opioid Overdose and Intranasal Naloxone Training for Law Enforcement Participant Manual Prepared by NYS Division of Criminal Justice Services NYS Department of Health NYS Office of Alcoholism and Substance

More information

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment

More information

Temple University Beasley School of Law. Project on Harm Reduction in the Health Care System

Temple University Beasley School of Law. Project on Harm Reduction in the Health Care System Temple University Beasley School of Law Project on Harm Reduction in the Health Care System DATE: March 20, 2008 MEMORANDUM RE: The legal requirements for operating an Opioid Antagonist Administration

More information

Increasing Issues of Polypharmacy and Off-Label Drug Use in Psychiatric Care

Increasing Issues of Polypharmacy and Off-Label Drug Use in Psychiatric Care Increasing Issues of Polypharmacy and Off-Label Drug Use in Psychiatric Care Stefan P. Kruszewski, MD Board Certified in Adult, Geriatric, Adolescent and Addiction Psychiatry, and Addiction Medicine Speaker

More information

New 7/1/2015 MCFRS 1

New 7/1/2015 MCFRS 1 New 7/1/2015 MCFRS 1 The providers will summarize the need for this change from an epinephrine auto injector The provider will define the proper dosage of epinephrine for the adult and pediatric patient

More information

INSTRUCTIONS FOR USE HUMIRA 40 MG/0.8 ML, 20 MG/0.4 ML AND 10 MG/0.2 ML SINGLE-USE PREFILLED SYRINGE

INSTRUCTIONS FOR USE HUMIRA 40 MG/0.8 ML, 20 MG/0.4 ML AND 10 MG/0.2 ML SINGLE-USE PREFILLED SYRINGE INSTRUCTIONS FOR USE HUMIRA (Hu-MARE-ah) (adalimumab) 40 MG/0.8 ML, 20 MG/0.4 ML AND 10 MG/0.2 ML SINGLE-USE PREFILLED SYRINGE Do not try to inject HUMIRA yourself until you have been shown the right way

More information

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII)

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental use by a child is a medical emergency

More information

Opioid Overdose TOOLKIT: Five Essential Steps for First Responders

Opioid Overdose TOOLKIT: Five Essential Steps for First Responders S A M H S A Opioid Overdose TOOLKIT: Five Essential Steps for First Responders TABLE OF CONTENTS FIVE ESSENTIAL STEPS FOR FIRST RESPONDERS Step 1: Call for Help (Dial 911) 3 Step 2: Check for Signs of

More information

Clinical Performance Director of Nursing Allison Bussey

Clinical Performance Director of Nursing Allison Bussey PGD 0314 Patient Group Direction Administration of Adrenaline (Epinephrine) 1:1000 (1mg/ml) Injection By Registered Nurses employed by South Staffordshire & Shropshire Healthcare Foundation NHS Trust This

More information

Opioid Agreement for Center for Pain Management S.C.

Opioid Agreement for Center for Pain Management S.C. Opioid Agreement for Center for Pain Management S.C. Patient Name: DOB: I am the patient named above. I have agreed to use pain medication as part of my treatment for chronic pain. I understand that these

More information

Substance Use: Addressing Addiction and Emerging Issues

Substance Use: Addressing Addiction and Emerging Issues MODULE 6: SUBSTANCE USE: ADDRESSING ADDICTION AND EMERGING ISSUES Substance Use: Addressing Addiction and Emerging Issues Martha C. Romney, RN, MS, JD, MPH Assistant Professor Jefferson School of Population

More information

Summary of the risk management plan (RMP) for Ionsys (fentanyl)

Summary of the risk management plan (RMP) for Ionsys (fentanyl) EMA/764409/2015 Summary of the risk management plan (RMP) for Ionsys (fentanyl) This is a summary of the risk management plan (RMP) for Ionsys, which details the measures to be taken in order to ensure

More information

The Professional Practice Committee Douglas E. Lentivech. September 8, 2015 SUMMARY

The Professional Practice Committee Douglas E. Lentivech. September 8, 2015 SUMMARY THE STATE EDUCATION DEPARTMENT / THE UNIVERSITY OF THE STATE OF NEW YORK / ALBANY, NY 12234 TO: FROM: SUBJECT: DATE: The Professional Practice Committee Douglas E. Lentivech Proposed Amendment to Section

More information